Xoma Corporation (XOMA) 0.64 $XOMA Biotech Industry's

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Xoma Corporation (XOMA) 0.64 $XOMA

Biotech Industry's Stocks Get Research Review
ACCESSWIRE - Fri Jun 03, 8:17AM CDT
LONDON, UK / ACCESSWIRE / June 3, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Biotechnology industry. Companies recently under review include XOMA, Vericel, Cara Therapeutics, and Regulus Therapeutics. Register with us now for your free membership and see our complete reports on these equities at:
CARA: 6.04 (+0.11), VCEL: 2.22 (-0.04), RGLS: 3.63 (+0.06), XOMA: 0.64 (-0.03)

XOMA to Present at the Jefferies Global Healthcare Conference
GlobeNewswire - Thu Jun 02, 12:48PM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that John Varian, the Company's Chief Executive Officer, is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 9, 2016, at 2:00 p.m. ET.
XOMA: 0.64 (-0.03)

Xoma reports 1Q loss
Automated Insights - Wed May 04, 4:47PM CDT
BERKELEY, Calif. (AP) _ Xoma Corp. (XOMA) on Wednesday reported a loss of $8.4 million in its first quarter.
XOMA: 0.64 (-0.03)

XOMA Reports First Quarter 2016 Operational Achievements and Financial Results
GlobeNewswire - Wed May 04, 3:01PM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced recent operational achievements and financial results for the first quarter ended March 31, 2016.
XOMA: 0.64 (-0.03)

XOMA Initiates XOMA 358 Proof-of-Concept Study in Patients with Hypoglycemia Post Gastric Bypass Surgery
GlobeNewswire - Wed Apr 27, 8:00AM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today it has initiated its proof-of-concept study to evaluate the safety and clinical pharmacology of a single dose of XOMA 358 in patients who experience dangerously low blood glucose levels (hypoglycemia) after undergoing gastric bypass surgery. XOMA 358 is a fully human allosteric monoclonal antibody that reduces both the binding of insulin to its receptor and downstream insulin signaling.
XOMA: 0.64 (-0.03)

Can The Uptrend Continue for XOMA Corp (XOMA)?
Zacks Equity Research - Zacks Investment Research - Tue Apr 19, 10:06AM CDT
Investors certainly have to be happy with XOMA Corporation (XOMA) and its short term performance
XOMA: 0.64 (-0.03)

4 Growth Stocks to Buy Near Their 52-Week Lows
Zacks Equity Research - Zacks Investment Research - Thu Apr 07, 8:14AM CDT
Several investors chose to cash in at current valuations thereby triggering a sell-off and exerting downward pressure on many fundamentally attractive stocks.
NSPR: 0.19 (+0.01), DSCO: 3.50 (-0.36), VNR: 1.72 (-0.03), XOMA: 0.64 (-0.03)

XOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO Meeting
GlobeNewswire - Mon Apr 04, 8:00AM CDT
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced the presentation of data from XOMA 129, the lead compound in the Company's XMetD antibody fragment (Fab) program, at the Endocrine Society's Annual Meeting - ENDO 2016. A senior scientist at XOMA presented the Company's poster titled "XOMA 129, a Novel Insulin Receptor Negative Modulator, is Efficacious in Treating Insulin- and Glibenclamide-induced Hypoglycemia in Animals."
XOMA: 0.64 (-0.03)

Xoma beats 4Q profit forecasts
Automated Insights - Wed Mar 09, 3:23PM CST
BERKELEY, Calif. (AP) _ Xoma Corp. (XOMA) on Wednesday reported fourth-quarter net income of $25.4 million, after reporting a loss in the same period a year earlier.
XOMA: 0.64 (-0.03)

XOMA Reports Fourth Quarter and Full-Year 2015 Financial Results
GlobeNewswire - Wed Mar 09, 3:01PM CST
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today reported the completion of its divestiture activities to focus the Company exclusively on advancing its portfolio of assets to address endocrine diseases, and provided its financial results for the quarter and year ended December 31, 2015.
XOMA: 0.64 (-0.03)

Posterior Uveitis Pipeline Review, H2 2015
M2 - Fri Jan 22, 5:35AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5g33c/posterior_uveitis) has announced the addition of the "Posterior Uveitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Posterior Uveitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Posterior Uveitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Posterior Uveitis Overview - Therapeutics Development - Pipeline Products for Posterior Uveitis - Overview - Pipeline Products for Posterior Uveitis - Comparative Analysis - Posterior Uveitis - Therapeutics under Development by Companies - Posterior Uveitis - Therapeutics under Investigation by Universities/Institutes - Posterior Uveitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Posterior Uveitis - Products under Development by Companies - Posterior Uveitis - Products under Investigation by Universities/Institutes - Posterior Uveitis - Companies Involved in Therapeutics Development - Aciont Inc. - Neuroptis Biotech - Oculis ehf - pSivida Corp. - Regeneron Pharmaceuticals, Inc. - ThromboGenics NV - Virogenomics, Inc. - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/l5...or_uveitis
REGN: 434.00 (+8.88), XOMA: 0.64 (-0.03)

Agenus grants stock options and restricted stock units to 28 new employees under NASDAQ Listing Rule 5635(c)(4)
M2 - Fri Jan 15, 4:31AM CST
Immunotherapy company Agenus (NasdaqCM:AGEN) Thursday awarded a total of 535,824 shares of its common stock.to 28 new employees in connection with its acquisition of XOMA Corporation's antibody manufacturing pilot plant.
AGEN: 5.65 (+0.10), XOMA: 0.64 (-0.03)

Agenus Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BusinessWire - Thu Jan 14, 3:01PM CST
Agenus Inc. (NASDAQ: AGEN), an immunotherapy company developing innovative treatments for patients with cancer, announced that in connection with its acquisition of XOMA Corporation's antibody manufacturing pilot plant it granted stock options and restricted stock units to 28 new employees covering a total of 535,824 shares of Agenus common stock. The awards were approved by Agenus' compensation committee and granted as inducements material to the new employees entering into employment with Agenus, as permitted under NASDAQ Listing Rule 5635(c)(4).
AGEN: 5.65 (+0.10), XOMA: 0.64 (-0.03)

Agenus Completes XOMA Antibody Manufacturing Pilot Plant Acquisition
BusinessWire - Mon Jan 04, 6:00AM CST
Agenus Inc. (NASDAQ:AGEN), an immunotherapy company developing innovative treatments for patients with cancer, announced today that it has completed the previously announced acquisition of XOMA Corporation's (NASDAQ: XOMA) antibody manufacturing pilot plant and capabilities. XOMA's experienced chemistry, manufacturing, and controls (CMC) team has joined Agenus and will continue to operate the facility. This pilot plant will enable the company to manufacture checkpoint modulator (CPM) antibodies for its own programs and those of its collaborators. The facility is expected to provide Agenus' antibody supply requirements through clinical proof-of-concept studies.
AGEN: 5.65 (+0.10), XOMA: 0.64 (-0.03)

Skin Ulcers Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Tue Dec 29, 11:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/glmghm/skin_ulcers) has announced the addition of the "Skin Ulcers Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Skin Ulcers Global Clinical Trials Review, H2, 2015" provides an overview of Skin Ulcers clinical trials scenario. This report provides top line data relating to the clinical trials on Skin Ulcers. It includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - XOMA Corporation - Nitta Gelatin India Limited - NB Therapeutics, Inc. - Abbott Laboratories - Aurous HealthCare Research and Development India Private Limited - AnGes MG, Inc. - Andaluz Health Service - Air Liquide S.A. - ACR Biologics, LLC For more information visit http://www.researchandmarkets.com/research/gl...kin_ulcers
ABT: 45.29 (+0.54), XOMA: 0.64 (-0.03)

Diabetic Nephropathy Pipeline Review, H2 2015 - Analysis & Opportunities
M2 - Tue Dec 29, 5:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/4pj8km/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H2 2015" report to their offering. The report Diabetic Nephropathy - Pipeline Review, H2 2015', provides an overview of the Diabetic Nephropathy's therapeutic pipeline. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics Companies Mentioned Include: - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca Plc - Bayer AG - BiOrion Technologies B.V. - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CSL Limited - GlaxoSmithKline Plc - Glucox Biotech AB - Pfizer Inc. - PhytoHealth Corporation - ProMetic Life Sciences Inc. - Serodus ASA - Shire Plc - Takeda Pharmaceutical Company Limited - Tobira Therapeutics, Inc. - Torrent Pharmaceuticals Limited - Vascular Pharmaceuticals, Inc. - Vicore Pharma AB - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/4pj8km/diabetic
PFE: 37.31 (+0.42), GSK: 45.25 (+0.18), CNCE: 11.82 (+0.33), AZN: 33.84 (-0.30), SHPG: 194.00 (-0.12), CCXI: 4.67 (-0.03), ABBV: 66.94 (+0.71), TBRA: 4.07 (-0.24), XOMA: 0.64 (-0.03)

Hyperprolactinaemia Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 5:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/lfwrst/hyperprolactinaemi) has announced the addition of the "Hyperprolactinaemia Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Hyperprolactinaemia Global Clinical Trials Review, H2, 2015" provides an overview of Hyperprolactinaemia clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperprolactinaemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Mylan N.V. - inVentiv Health, Inc. - Endo International Plc - XOMA Corporation - Merck KGaA - Johnson & Johnson For more information visit http://www.researchandmarkets.com/research/lf...lactinaemi
JNJ: 125.40 (+0.17), XOMA: 0.64 (-0.03)

Direction of Market Influences - Research Reports on Iridium Communications, XOMA, Horsehead Holding and LSB Industries
ACCESSWIRE - Mon Dec 14, 7:25AM CST
NEW YORK, NY / ACCESSWIRE / December 14, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Iridium Communications Inc. (NASDAQ: IRDM), XOMA Corp (NASDAQ: XOMA), Horsehead Holding Corp (NASDAQ: ZINC) and LSB Industries Inc. (NYSE: LXU). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
ZINC: 0.08 (-0.01), IRDM: 8.82 (-0.16), LXU: 11.65 (+0.07), XOMA: 0.64 (-0.03)

Fibrosis - Pipeline Review, Technologies & Forecast Report H2 2015
M2 - Tue Dec 08, 3:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/7qfnt7/fibrosis) has announced the addition of the "Fibrosis - Pipeline Review, H2 2015" report to their offering. The report Fibrosis - Pipeline Review, H2 2015', provides an overview of the Fibrosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibrosis and special features on late-stage and discontinued projects. Key Topics Covered: - The report provides a snapshot of the global therapeutic landscape of Fibrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Fibrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Benefits of this Report: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fibrosis - Devise corrective measures for pipeline projects by understanding Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned Include: - Abeome Corporation - Acceleron Pharma, Inc. - Complexa, Inc. - Digna Biotech, S.L. - F. Hoffmann-La Roche Ltd. - FibroGen, Inc. - GlycoMimetics, Inc. - HanAll Biopharma Co., Ltd. - Isarna Therapeutics GmbH - Lycera Corp. - miRagen Therapeutics, Inc. - Neumedicines Inc. - Ribomic Inc. - RuiYi Inc. - Siena Biotech S.p.A. - SK Chemicals Co., Ltd. - XOMA Corporation For more information visit http://www.researchandmarkets.com/research/7qfnt7/fibrosis
GLYC: 8.84 (+0.49), FGEN: 19.73 (+0.60), XOMA: 0.64 (-0.03), XLRN: 34.40 (+0.48)

The Zacks Analyst Blog Highlights: Repros Therapeutics, AbbVie, Amgen, XOMA and Gilead
Zacks Equity Research - Zacks Investment Research - Thu Dec 03, 8:30AM CST
The Zacks Analyst Blog Highlights: Repros Therapeutics, AbbVie, Amgen, XOMA and Gilead
GILD: 80.46 (+0.99), AMGN: 174.16 (+2.13), RPRX: 2.06 (-0.06), ABBV: 66.94 (+0.71), XOMA: 0.64 (-0.03)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 162

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data

Updated Category News Views 35

A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 10

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 72

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 183

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 117

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Markel Elevates War Risk Expertise in London Market

Updated Category News Views 73

A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...

Continue Reading
Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 231

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 194

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 16

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Generative AI Chipset Market Growth

Updated Category News Views 252

Generative AI Chipset Market Size Analysis The Generative AI Chipset Market is experiencing remarkable growth as the demand for high-performance AI hardware accelerates across various industries. Currently valued at approximately USD 37.29 billion in 2023, the market is anticipated to reach an impressive USD 454.50 billion by 2032, representing a staggering compound...

Continue Reading
CrateDB Welcomes Robert Ekstrom as New Chief Executive Officer

Updated Category News Views 297

CrateDB Welcomes Robert Ekstrom as New Chief Executive Officer CrateDB, the groundbreaking real-time database solution designed for analytics, search, and AI applications, has announced the exciting appointment of Robert Ekstrom as the new Chief Executive Officer. His leadership is viewed as a pivotal moment for the company, propelling its growth strategies and...

Continue Reading
Novartis AGM Highlights: Board Changes and Dividend Increase

Updated Category News Views 463

Key Outcomes from Novartis' Annual General Meeting Today, Novartis held its Annual General Meeting (AGM) where shareholders gathered to discuss and approve various resolutions proposed by the Board of Directors. It was an important day for the company, as a strong turnout highlighted investor engagement and confidence. Dividend Increase for 2024 This year marks a...

Continue Reading
Understanding Alliance Witan PLC's Net Asset Valuation Insights

Updated Category News Views 116

Understanding Alliance Witan PLC's Financial Standing Alliance Witan PLC stands out in the investment landscape, offering its shareholders a detailed look at their Net Asset Value (NAV). As of the latest reporting date, the financial metrics reveal significant information pertaining to the company's performance and shareholder value. Net Asset Value Calculation At the...

Continue Reading
Remembering Jimmy Carter: A Legacy of Service and Humanity

Updated Category News Views 375

Remembering Jimmy Carter: A Legacy of Service and Humanity Habitat for Humanity joins millions around the globe in reflecting on the remarkable life of former U.S. President Jimmy Carter. He is widely recognized not only as a political leader but also as a formidable advocate for affordable housing. A Champion for Affordable Housing Throughout his life, President Carter...

Continue Reading